|1.||Hou, X: 1 article (06/2001)|
|2.||Lachapelle, P: 1 article (06/2001)|
|3.||Beauchamp, M H: 1 article (06/2001)|
|4.||Speranza, G: 1 article (06/2001)|
|5.||Quiniou, C: 1 article (06/2001)|
|6.||Chemtob, S: 1 article (06/2001)|
|7.||Abran, D: 1 article (06/2001)|
|8.||Martinez-Bermudez, A K: 1 article (06/2001)|
|9.||Varma, D R: 1 article (06/2001)|
|10.||Gobeil, F: 1 article (06/2001)|
|2.||Body Weight (Weight, Body)
06/01/1996 - "Clinicopathologic and renal histopathologic changes induced by gentamicin (10 mg/kg of body weight, IM, q 8 h, for 8 days) were compared in dogs fed an n-3 fatty acid-supplemented diet containing a fatty acid ratio of 5.7:1 (n-6:n-3), dogs treated with CGS 12970 (a specific TXSI given at 30 mg/kg, PO, q 8 h, beginning 2 days prior to gentamicin administration), and control dogs. "
11/01/1990 - "A specific thromboxane synthetase inhibitor, 3-methyl-2 (3-pyridyl)-1-indoleoctanoic acid (CGS 12970) was administered orally to 6 healthy adult Beagles at a dosage of 30 mg/kg of body weight. "
05/01/1992 - "Starting 4 weeks after renal arterial infusion, 6 dogs were treated orally 3 times daily with 30 mg of 3-methyl-2 (3 pyridyl)-1-indolectanoic acid (CGS 12970)/kg of body weight, a thromboxane synthetase inhibitor, and 6 dogs (control group) received a gelatin capsule 3 times daily. "
09/01/1992 - "Platelet aggregation and adenosine triphosphate (ATP) secretion in response to arachidonic acid (10 microM) or collagen (5 micrograms/ml) were compared in healthy, adult female Beagles treated with low-dosage aspirin (3.5 mg/kg of body weight, PO, q 12 h for 7 treatments) or with CGS 12970, a specific thromboxane synthetase inhibitor (10 mg/kg, PO, q 8 h for 10 treatments). "
06/01/1986 - "A new thromboxane synthetase inhibitor, CGS-12970, was evaluated for its ability to reduce the extension of myocardial infarct size in rats. "
01/01/1988 - "The results suggest that the thromboxane synthetase inhibitor, CGS 12970, when administered in the subacute phase of recovery from myocardial infarction, does not protect against the induction of ventricular tachycardia by programmed electrical stimulation or the spontaneous development of ventricular fibrillation in the postinfarcted canine heart. "
07/01/1987 - "A specific inhibitor of thromboxane A2 (TxA2) synthesis, CGS-12970, a new angiotensin-converting enzyme (ACE) inhibitor, CGS-16617, and a combination of both agents were evaluated for their ability to reduce the extension of myocardial infarct size in rats. "
|4.||Renal Insufficiency (Renal Failure)
|5.||Pregnancy-Induced Hypertension (Hypertension, Pregnancy Induced)
09/01/1992 - "Changes in maternal and fetal umbilical arterial vasoreactivity during ovine pregnancy-induced hypertension and following intravenous administration of CGS 12970 [3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid] were assessed. "
09/01/1992 - "Continuous wave Doppler flow velocimetry was used to assess vascular reactivity during normotensive baseline, during ovine pregnancy-induced hypertension triggered by a 72-hour fast, and following thromboxane synthetase inhibition with CGS 12970. "
|5.||Thromboxane A2 (A2, Thromboxane)
|7.||Arachidonic Acid (Vitamin F)
|9.||p-Aminohippuric Acid (p-Aminohippurate)
|10.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|1.||Homologous Transplantation (Allograft)